To appraise the clinical and cost effectiveness of nivolumab in combination with platinum-doublet chemotherapy within its marketing authorisation for untreated PD-L1-negative non-small-cell lung cancer.
Status In progress
Process STA pre-2018
ID number 1135

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
18 July 2019 Draft scope documents
11 September 2017 - 09 October 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
12 September 2017 In progress, In progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance